TW201139605A - Hydrous adhesive patch - Google Patents

Abstract

Disclosed is a hydrous adhesive patch which contains a drug, has excellent re-adhesion, and is less painful when peeled off the skin. The disclosed hydrous adhesive patch is provided with a support body and an adhesive layer disposed on said support body. The adhesive layer is a preparation of a drug, water (at no more than 30% of the total mass of the adhesive layer), and polyhydric alcohols (at no less than 40% of the total mass of the adhesive layer). The polyhydric alcohols optimally include glycerin. The adhesive layer further contains an inorganic powder, and the sum of the amounts of said inorganic power and the polyhydric alcohols preferably makes up at least 50% of the total mass of the adhesive layer.

Description

201139605 VI. Description of the Invention: TECHNICAL FIELD OF THE INVENTION The present invention relates to an aqueous patch containing a drug. [Prior Art] Previously, the drug was percutaneously absorbed by an aqueous patch for the purpose of slow release and localized supply of the drug. For example, it is known that lidocaine (hdocaine) functions as a palliative for persistent pain such as herpes zoster or post-herpetic neuralgia, a local anesthetic, etc., because in such applications, the drug is slowly released. It is particularly important that the drug is delivered to the patient's body and the drug is delivered to the local affected part. Therefore, the applicator is attracting attention by percutaneous absorption compared to the route of administration such as oral administration and injection (Patent Document 1). [Prior Art Document] (Patent Document) Patent Document 1: JP-A-KOKAI Publication No. 4-305523 SUMMARY OF THE INVENTION [Problems to be Solved by the Invention] However, the prior adhesive is suitable even if the initial adhesion is appropriate.

After sticking to the skin, the viscous force of the six-dollar A-type is too strong, so it is accompanied by a considerable amount of pain from the skin (4) after use. In particular, for patients with banded therapy or with (4) money (four) continuous pain, etc., it is very important to attach the pain when the 201139605 agent is peeled off. 'Because the patch is necessary to stick to the affected area for a long time, especially persistent pain such as herpes zoster or post-herpetic neuralgia, because most of it is attached to the position of the frequency of the joints, etc. Activity, the part of the patch has the possibility of peeling off. However, in this case, the previous patch also has a problem that it is difficult to stick to the skin. The present invention has been made in view of the above circumstances, and an object thereof is to provide an aqueous patch which contains a drug such as lidocaine and which can alleviate pain suffered by a user when peeled off, and which has excellent re-adhesion. [Means for Solving the Problem] The present inventors have found that the amount of water is suppressed to 30% by mass or less relative to the total mass of the adhesive layer, and at the same time, the a _u 砰隹 adhesive layer is blended with respect to The total mass of the adhesive layer is 40 mass. / 〇 〇 〇 晋 ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ Specifically, the present invention provides the following. (1) An aqueous patch comprising a support and an adhesive layer on the support. The aqueous patch is prepared by disposing the following in the adhesive layer: a drug; 7jc, The amount of the total amount of the adhesive layer is 30% by mass or less; and the amount of the polyol is 40% by mass or more based on the total mass of the underlayer. (2) For example, (aqueous binder of the hydrazine, wherein the aforementioned polyol contains glycerin.

(3) The aqueous patch according to (1) or (2), which further contains an inorganic powder and the total amount of the inorganic powder and the aforementioned polyol is 50 mass with respect to the total mass of the aforementioned adhesive layer of 201139605 . /〇 above. (4) The aqueous patch according to any one of (1) to (3), wherein the drug contains lidocaine and/or a pharmacologically acceptable salt thereof. (5) The aqueous patch according to any one of (1) to (4), which is for use in the treatment or prevention of herpes zoster or post-herpetic neuralgia. [Efficacy] According to the present invention, the amount of water in an amount of 30% by mass or less based on the total mass of the adhesive layer and the total mass of the adhesive layer is 40 mass 〇/〇 or more. Since the polyol is used, it is possible to suppress an increase in the adhesive force, and it is possible to reduce the pain of the user at the time of peeling, and at the same time, to improve the adhesion. [Embodiment] [Best Mode for Carrying Out the Invention] Hereinafter, embodiments of the present invention will be described, but the present invention is not limited thereto. The aqueous patch of the present invention comprises: a support; and an adhesive layer on the support and containing a drug. The details of each element are explained below. [Adhesive layer] The water-based patch of the present invention is formulated in an amount of 30% by mass or less based on the total mass of the adhesive layer with respect to the total mass of the adhesive layer, and 40% by mass or more based on the total mass of the adhesive layer. The amount of polyol. Thereby, it is possible to suppress an increase in the adhesive force and at the same time, it is possible to increase the adhesion. 201139605 The amount of water to be formulated is 3% by mass or more, more preferably 28%, as long as the formulation can be tolerated. /. The following ranges are appropriately selected. Further, the lower limit of the amount of water to be blended is such that when the amount of water is too small, the amount of other components (for example, glycerin or the like) is increased, so that the production cost is increased, and a sufficient amount of other components (for example, polyacrylic acid and/or a salt thereof) are not In the case of dissolution or the like, it is usually 10% by mass, more preferably 15% by mass, based on the total mass of the pressure-sensitive adhesive layer. The blending amount of the polyol may be appropriately selected from the above range, but it is preferably 40% by mass or more based on the total mass of the adhesive layer from the viewpoint of suppressing the increase in the adhesive force and improving the excellent re-adhesion. It is better to use 5 〇 or more. Further, the upper limit of the blending amount of the polyol can be appropriately set in consideration of the amount of water to be formulated, the production cost, and the easiness of bleeding. Examples of the polyhydric alcohol include glycerin, sorbitol, ethylene glycol, propanol, polyethylene glycol, polypropylene glycol, and 13-butanediol (i3butylene, 1,3-butanediol (1, 3). -13 plus 玨116€11〇1), 1,4-butanediol, 1,2,6-=-alcohol, maltitol (mahit〇1) and xylitol (xyHt〇1). There are one or a combination of two or more kinds, and it is preferable to contain glycerin. The glycoside contains concentrated glycerin (the glycerin content is 98 〇 and other glycerol (glycerin content is 84 to 87%)' is not particularly limited. However, it is more preferable to use concentrated glycerin (glycerin content: 98.0 to 101.0%). The drug system is not particularly limited, and any one may be treated according to the use of the god: water patch in accordance with the present invention. For the purpose of preventing pain, a local anesthetic and various analgesics may be mentioned. In the case of 201139605, tetracaine, procaine, dibucaine, Lidocaine, benzocaine, mexiletine, r〇pivacaine, and their pharmacology A local anesthetic such as an acceptable salt; indomethacin, ketoprofen, piroxicam, fe丨binac, bufexamae, Suprofen, flurbiprofen, diclofenac, ibuprofen, loxoprofen (1〇x〇pr〇fen), amfenic acid ( Amfenac), and other non-steroidal anti-inflammatory analgesics such as pharmacologically acceptable salts; anti-depressants such as amitriptyline; anti-caries such as gabapentin; dehydrogenated cortex Steroids such as prednisolone; capsaicin, acetaminophen, aspirin, codeine phosphate, amitriptyUne, naproxen ), phenacetin, vaccinia virus, other towns such as inflammatory skin extracts, etc. (4). The towel is preferably a local anesthetic, with lidocaine and/or its pharmacologically acceptable salt. For better. As published in the Japanese Pharmacopoeia, Due to a system for drug T㈣ thereof: persistent pain of postherpetic neuralgia after herpes, or ribbon demulcent, a local anesthetic, antiarrhythmic drugs. The lidocaine contained in the adhesive layer is mainly in a free form, but may be in the form of a pharmacologically acceptable salt. The pharmacologically acceptable salt system is not particularly limited, and a hydrochloride salt is preferred. The amount of lidocaine and/or its pharmacologically acceptable salt (hereinafter also referred to as Lee 201139605 &quot; member) is not particularly limited, but when too much, lidocaine will be precipitated and difficult to store. In the preparation, on the other hand, when it is too small, it is difficult to get enough effect. Therefore, the amount of the lidocaine is preferably from 01% by mass to 5% by mass based on the total mass of the adhesive layer, and preferably from 3% by mass to 3% by mass, and preferably 3% by mass. 1% by mass is more preferable, and 5% by mass is most preferable. The adhesive layer may contain, in addition to the above components, an excipient, a crosslinking agent, and a crosslinking control agent containing t Hn surfactant, N-methyl group, polyacrylic acid, and/or a salt thereof as necessary. , adhesion enhancer, lidocaine dissolution aid, pH adjuster, coolant, water-soluble door knife. Any component of materials, inorganic powders, antioxidants, preservatives, pigments, etc. The inorganic powder may, for example, be kaolin, oxidized, oxidized, anhydrous (tetra) or light-frozen, and these may be contained alone or in combination of two or more. Inorganic powders inhibit excessive adhesion. Therefore, the amount of the total inorganic powder to be added to the pressure-sensitive adhesive layer is preferably 5% by mass or more based on the total amount of the polyol. One of the advantages of the aqueous patch of the present invention is that the effect of suppressing an increase in the adhesive force is exhibited by blending the above-mentioned amount of water and a polyol in the adhesive layer. For example, the aqueous patch may contain a surfactant or the like, but even if it is not contained, it has an excellent effect of suppressing an increase in adhesion. The surfactant is not particularly limited. Examples include sorbitan sesquioleic acid sucrose anhydride monolaurate, sorbitan-palmitic acid vinegar, mountain mid-mountain sugar-anhydride-stearate, etc. 201138605 sorbitol fatty acid vinegar Glycerol fatty acid vinegar such as glycerin monostearate; glycerol glycerol sulphate, glycerol oleate, polyglycerol fatty acid oxime, polyethylene glycol distearate, polyethylene glycol Polyethylene glycol fatty acid ester such as stearic acid vinegar; polyoxygen # 7 AI kp milk / glutinous ethyl sorbitan trioleate, polyoxygen ethene, sorbitan monooleic acid vinegar, etc. Polysorbate, polysorbate, ethyl sorbitol, tetraoleate, etc., polyoxyethylene, sorbitol, sorghum, sorghum, polyoxyethylene, glycerol, oleate, etc. Ethylglycerol fatty acid 酉曰 'polyoxy-extension ethyl laurate shout, polyoxy-extension ethyl sulfonate test and other polyoxyethylene ethyl ether; polyoxy-extension ethyl polyoxypropyl propyl cetyl ether, poly Oxygen-extended ethyl polyoxyl extended propyl fluorenyl sulphide _ _ polyoxy-extension ethyl polyoxy-extension two-alkyl ether; polyoxy-extension ethyl hard acetamide and other polyoxyethylene Fatty acyl amine; polyoxyethylene extending ethyl castor oil, polyoxyethylene hardened castor oil and the like extending ethyl surfactant; these may be contained alone! The species or combination contains two or more kinds. There is no particular sputum polyoxyethylene sorbitol liver fatty acid g, preferably polyoxyethylene ethyl sorbitan trioleate, polyoxyethylene sorbitan monooleate (POLYSORBATE 80) ) is suitable. The pH of the W1 layer is preferably adjusted to 4·5 to 9, preferably adjusted to 6 to 7.4. When it is less than 4 5, the transferability of the drug, particularly lidocaine, to the skin is deteriorated. Therefore, the pH of the adhesive layer is preferably 4.5 or more. Thus, in the weakly acidic pH region, it is preferred to use a crosslinking agent which is generally different from the commonly used crosslinking agent, specifically, dihydroxy aluminum acetate. (alias: aluminum aluminate; alUmium glycinate). The aluminum of the aluminum dihydroxy aluminum acetate is well eluted in the vicinity of weakly acidic to neutral, and can be crosslinked with a polyacrylic acid (salt) or the like which will be described later. 201139605 Further, 'as a crosslinking agent, it is not limited by the aminoacetic acid diamide, and a polyvalent metal salt is mentioned. Among them, an aluminum compound is preferred. Examples of the aluminum compound include hydroxides of dihydroxy aluminum acetate, aluminum hydroxide, and aluminum hydroxide as described above; or inorganic acids such as vaporized aluminum, aluminum sulfate, aluminum acetate, and stearic acid. Or a salt of an organic acid; for example, a double salt of aluminum alum; a salt of sodium aluminate; an inorganic aluminum salt; and an organic aluminum compounding compound. These aluminum compounds may be water-soluble or poorly soluble. Further, the 'PH system can be set using a pH adjuster, and as such a pH adjuster', tartaric acid, scaly acid, malic acid, citric acid, hydrochloric acid, sodium hydroxide, triethanolamine, diethanolamine, diisopropanol can be mentioned. The amine or the like may be contained alone or in combination of two or more kinds, and tartaric acid or phosphoric acid is preferred. Examples of the polyacrylic acid and/or its salt include polyacrylic acid, sodium polyacrylate, and polyacrylic acid partial neutralizing products "NP-800 (trade name)" and "NP-700 (product name)" (made by Showa Denko Corporation). And the like, these may be contained alone or in combination of two or more. Examples of the adhesion enhancer include methacrylic acid-n-butyl acrylate copolymer, methyl acrylate-2-ethylhexyl acrylate copolymer, polybutene ester gum, terpene resin, and alicyclic ring. A saturated hydrocarbon resin or the like. The blending amount may be 5% by mass or more and 3% by mass or less, and preferably 5% by mass or more and 2% by mass or less, based on the total mass of the pressure-sensitive adhesive layer. Examples of the crosslinking agent controlling agent include sodium edetate (disodium diethylene tetraacetate), citric acid, and the like, and these may be contained alone or in combination of two. More than the above, sodium edetate is preferred. 201139605 As a dissolution aid for drugs, particularly lidocaine, examples include crotamiton, N-methyl-2-pyrrolidone, peppermint oil, and 1,3-butanediol. These may be contained alone or in combination of two or more. As the coolant, camphor, thyrrol, and 1-menthol, dl-menthol, 2-mercapto-3-(1-menthyloxy)propane_1,2- Glycol (2-methyl-3-(l-menthyloxy)propane-l,2-diol), 3-(1-menthyloxy)propane-1,2-diol, 2-hydroxypropionic acid 5-methyl A menthol derivative such as benzyl-2-(1-methylethyl)cyclohexanacetate or the like may be contained alone or in combination of two or more. Examples of the water-soluble polymer compound include gelatin, agar, polyvinyl alcohol, polyvinylpyrrolidone, propyl carbonate, carboxymethyl cellulose, sodium carboxymethyl cellulose, hydroxypropyl cellulose, and hydroxypropyl Base thiol cellulose, hydroxyethyl cellulose, methyl cellulose, sodium alginate, maleic anhydride copolymer, carrageenan, etc., which may be contained alone or in combination of two the above. Examples of the antioxidant include tocopheryl acetate, ascorbic acid, and/or any of its organisms, sodium sulfite, sodium hydrogen sulfite, sodium metabisulfite, sodium nitrite, dibutyl hydroxy benzene, and the like. Or a combination of two or more types. Examples of the preservative include decyl p-hydroxybenzoate, p-hydroxybenzoic acid I, propyl p-hydroxybenzoate, butyl p-hydroxybenzoate, and thymol, and these may contain hydrazine alone. The species or combination contains two or more kinds. The type of the dye is not particularly limited, and examples thereof include the pigments contained in the Handbook of the Legal Coloring matter, and the above-mentioned types may be used alone or in combination of two types of 201139605 or more. [Support] The support system may be composed of a woven fabric, a nonwoven fabric, a woven fabric, or the like, a resin film, a paper, and the like which are previously known for use as a patch. The material of the support may be selected from the group consisting of polypropylene, polyethylene, polybutene, polyethylene terephthalate, rayon, cotton, and polyurethane. Further, two or more kinds are not particularly limited, and polyethylene terephthalate is preferred. In terms of cost, it is preferred to use a support composed of a non-woven fabric formed of polyethylene terephthalate. Further, when a resin film is used, it is also possible to use a paint which is printed or kneaded with a white skin color or the like to perform coloring, or to store a branch of a character or the like, and to improve the adhesion of the adhesive, it is also possible to use the film. A branch body of a polyurethane treatment, a matting treatment, or the like is performed. [Peeling liner] The patch of the present invention may further comprise a release liner covering the adhesive layer. As such a release liner, a resin film such as polyethylene terephthalate or polypropylene is preferred. A person who has been subjected to a peeling treatment such as Shixia or the like may be used. Further, it is also possible to use a painter who is printed or kneaded to push white or the like as a release liner. The above patch can be used for any purpose in accordance with the main formulated drug. However, as a particularly useful ♦, treatment or prevention of persistence such as banding _ or banded cancer after neuralgia can be mentioned. The adhesive of the present invention can reduce the pain during use and maintain a long-lasting adhesion when it is peeled off, and can be easily reattached because of the excellent 12 201139605. (Preparation method) The patch of the present invention can be prepared by a conventional method, and can be prepared by the following method: the above-mentioned essential components and, if necessary, the appropriate preparations are appropriately prepared and kneaded by a known method. After evenly spreading on the release liner so that the mass of the adhesive per unit area of the patch is 0.03 to 〇.i5 g/cm, the support is further laminated on the adhesive layer, and then cut. Become 100mmxl40mm (four) shape. Alternatively, it may be prepared by stretching the adhesive on the support body and then laminating the release layer thereon. The present invention will be specifically described below by showing the examples and comparative examples, but the present invention is not limited by the examples. [Examples] &lt;Examples i to U, Comparative Examples 1 to 3&gt; The examples and the examples of the vehicle examples were obtained by mixing the components indicated in Tables 3 to 3 for a predetermined period of time. Each of the adhesives (i4〇mmxi〇〇mm) has an adhesive mass of about 14 g. The peeling is uniformly performed on the peeling profile. The surface of the adhesive layer is bonded with polyethylene terephthalate. After the non-woven fabric Ik, the cutting is made to a size of 1 mm x 14 mm, and the amount of the patch X is shown in Tables 1 to 3. /〇. 13 201139605 [Table i] Formulation of ingredients, implementation, implementation, implementation, implementation, implementation, comparison, comparative example, 1 case, 2 cases, 4 cases, 4 cases, 5 cases, 6 cases, 1 case 2, case 3, lidocaine, 5 N-mercapto-2-pyrrolidine Ketone 2 Polyoxyethylene sorbitan trioleate (TO-30: manufactured by Nikko CHEMICALS Co., Ltd.) 0.3 Concentrated glycerin 52.15 30.00 40.00 30.00 1,3-butanediol 0 22.15 0 0 0 0 0 0 0 Propylene glycol 0 0 22.15 0 0 0 0 0 0 Polyethylene glycol (PEG) 400 0 0 0 22.15 0 0 0 0 0 1,2,6-hexanetriol 0 0 0 0 24.15 0 0 0 0 Ethanol 0 0 0 0 0 0 24.15 0 0 Kaolin 0 0 0 0 0 14.15 0 24.15 0 Purified water 28 52 Sodium polyacrylate 1 Polyacrylic acid partially neutralized Aminoacetic acid dihydroxyaluminum 0.5 Sodium edetate 0.2 Carboxymethyl cellulose sodium 3 Hydroxybenzene Methyl Formate 0.2 Sodium Sulfite 0.3 pH Adjuster Appropriate Total 100 Adhesive Quality (g/140cm2) 14.0 Adhesion (g/2.5cm) 60.2 44.7 44.5 41.5 67.5 80.8 101.5 104.0 132.0 Pain at Peel ◎ ◎ ◎ ◎ ◎ 〇 XXX re-adhesion (g/2.5cm) 19.9 18.0 20.0 20.0 17.3 23.9 7.5 11.7 12.2 14 201139605 [Table 2] Formulation Ingredient Example 7 Example 8 Example 9 Lidocaine 5 5 5 N-mercapto-2-pyrrolidone 2 1 5 Polyoxyethylene sorbitan trioleate (TO -30: Twilight CHEMICALS company) 0.3 0.5 0.5 concentrated glycerin 54 60 50 purified water 28 20 25 titanium oxide 0.2 0 0.4 light anhydrous citric acid 1 2 0 gelatin 1.5 0 2.5 polyacrylic acid partial neutralizer 4 4 5 amine Dihydroxy aluminum acetate 1 1 0.8 sodium edetate 0.15 0.1 0.2 sodium carboxymethyl cellulose 2 4 4 propyl p-hydroxybenzoate 0.1 0.1 0.2 sodium sulfite 0.05 0 0.2 pH adjuster amount 100 total adhesive mass (g/ 14〇cm2) 14.0 Adhesion (g/2.5cm) 60 58 55 Pain at the time of peeling ◎ ◎ ◎ Re-adhesion (g/2.5cm) 20 21 19 15 201139605 [Table 3] Example 10 Example 11 Lidocaine 5 5 N-mercapto-2-pyrrolidone 2 0 POLYSORBATE 80 0.3 0.3 concentrated glycerol 54 56 purified water 28 28 titanium oxide 0.2 0.2 light anhydrous citric acid 1 1 gelatin 2 2 polyacrylic acid partial neutralizer 4 4 amine group Dihydroxyaluminum acetate 0.5 0.5 sodium edetate 0.15 0.15 sodium carboxymethylcellulose 2 2 p-hydroxyphenylhydrazine Acid oxime ester 0.1 0.1 propyl parahydroxybenzoate 0.05 0.05 sodium sulfite 0.05 0.05 pH adjuster amount appropriate amount 100 100 Adhesive mass (g / 140cm2) 14.0 14.0 Adhesion (g / 2.5cm) 63.5 55.5 When peeling Pain ◎ ◎ Reattaching force (g/2.5 cm) 24 23 (Test Example 1) Adhesion to the skin The patch of each of the examples and the comparative examples was cut into 2.0 x 3.0 cm and attached to the front wrist portion of the human body. After 8 hours, the "Sun Rheo Meter CR-200D" (manufactured by Sun Scientific Co., Ltd.) was used and measured at a speed of 300 mm/min in a direction of 180 degrees with respect to the skin according to the test method of JIS Z 0237. Peel force when the patch is peeled off. As shown in Tables 1 to 3, in comparison with Comparative Examples 1 to 3, Examples 1 to 11 16 201139605 had a low adhesive force, but had a necessary adhesive force of 啕.5 g / 2.5 cm or more. In fact, the embodiment]~彳, Β Β _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ (Test Example 2) Pain at the time of peeling In the test example 1, the degree of the consumption when peeling from the front wrist portion of the human body after 8 hours was evaluated by the eight testers. Also, the evaluation criteria are as follows. ◎: No pain at all. 〇: I don't feel pain. △: I feel a little strong pain and the skin is pulled. X. Feeling intense pain and suffering. As shown in Tables 1 to 3, in comparison with Comparative Examples 1 to 3, Examples 1 to 1 j greatly reduced the pain at the time of peeling. In particular, in the examples 丨~5, 7~11', the pain at the time of peeling was not felt at all. (Test Example 3) Reattachment to the skin The patch after 8 hours was temporarily peeled off from the skin and attached to the skin again. Subsequently, the peeling force was measured in the same procedure as in Test Example 1. As shown in Tables 1 to 3, in comparison with Comparative Examples i to 3, the adhesion of Examples 1 to i i was higher after the adhesion, and the adhesion was excellent. <Examples 12 to 13> The patch was prepared in the same manner as in Example 1 except that the components shown in Table 4 were blended. 17 201139605 [Table 4] Formulation ingredient amount (% by mass) Example 12 Example 13 Lidocaine 5 N-mercapto-2-pyrrolidone 0 2 Polyoxyethylene sorbitan trioleate ( TO-30: Nissan CHEMICALS company) 0 0.3 Concentrated glycerin 54.2 51.9 Purified water 28 Sodium polyacrylate 1 Polyacrylic acid partial neutralizer 5 Aminoacetic acid dihydroxy aluminum 0.5 Sodium edicate 0.2 0.2 Sodium carboxymethyl cellulose 3 Methyl benzoate 0.2 Sodium sulfite 0.3 pH adjuster Appropriate amount 100 Adhesive mass (g/14〇cm2) 14.0 (Test Example 4) Skin permeability of lidocaine in hairless mice mounted in a vertical diffusion tank The recipient of the dermis layer on the skin (purchased from SLC, Japan) was taken out, and 1.2 mL of 0.05 mol/L Mcllvain buffer (pH 7.4) was added, and the side of the stratum corneum was applied. A 1.77 cm2 piece of adhesive layer of each patch was attached to the donor. Subsequently, after 24 hours, 0.6 mL of the body fluid was taken at each predetermined time, and the concentration of lidocaine in the body fluid was measured by HPLC (High Performance Liquid Chromatography). Again, after taking 0.6 mL, the recipient was supplemented with 0.6 mL of new 0.05 mol/L Maquiban buffer. The lidocaine cumulative permeation amount of 24 hours from the total concentration of lidoca 18 201139605 measured at each time point is shown in Table 5. [Table 5] Example 12 Example 13 Comparative Example 3 Accumulated skin permeation amount (pg/cm2/24 hours) 314 339 270 As shown in Table 5, Examples 12 to 13 were able to obtain the same or more as Comparative Example 3. Percutaneous absorption of cain. Thereby, in addition to the above-mentioned increase in adhesion and re-adhesion, it was confirmed that the transdermal absorbability of the drug was improved. [Simple diagram description] None [Main component symbol description] None 19

Claims (1)

201139605 VII. Patent application scope: 1. An aqueous patching agent comprising a support body and an adhesive layer on the support body, wherein the aqueous patching agent is prepared by mixing the following in the adhesive layer: The drug; water is an amount of 30% by mass or less based on the total mass of the pressure-sensitive adhesive layer; and the polyol is an amount of 40% by mass or more based on the total mass of the pressure-sensitive adhesive layer. 2. The aqueous patch according to claim 1, wherein: the polyol comprises glycerin. 3. The aqueous patch according to claim 1, wherein: the inorganic powder is further contained and the sum of the inorganic powder and the polyol is relative to the total mass of the adhesive layer. It is 50% by mass or more. 4. The aqueous patch according to claim 2, wherein: the inorganic powder is further contained and the sum of the inorganic powder and the polyol is 'the total mass of the adhesive layer relative to the foregoing It is 50% by mass or more. The aqueous patch according to claim 1, wherein: the drug comprises lidocaine and/or a pharmacologically acceptable salt thereof. • An aqueous patch as described in claim 2, wherein: the drug comprises lidocaine and/or a pharmacologically acceptable salt thereof. The aqueous patch according to Item 3 of the Patent Application, wherein: 20 201139605 The aforementioned medicine contains a step. πDocaine and/or its pharmacologically acceptable 8. For example, the application of the patent 圊 圊 & 驶 驶 固 固 固 含水 含水 含水 含水 含水 含水 含水 含水 含水 含水 含水 含水 含水 含水 含水 含水 含水 含水 含水 含水 含水 含水 含水 含水 含水 含水 含水/ or its pharmacologically acceptable salt. The aqueous patch according to any one of claims 1 to 8, which is for use in the treatment of preventing herpes zoster or post-herpetic neuralgia. 21 201139605 IV. Designated representative map: (1) The representative representative of the case is: None. (2) A brief description of the symbol of the representative figure: None. 5. If there is a chemical formula in this case, please disclose the chemical formula that best shows the characteristics of the invention: